Interim Report 3 2024/25
13 mars, 2025
Interim Report 3 2024/25
NOVEMBER 2024 – JANUARY 2025
Net sales | 6 481 (4 873) KSEK |
Operating result before depreciation (EBITDA) | -987 (-3 179) KSEK |
Net result | -2 681 (-5 152) KSEK |
Earnings per share | -0.08 (-0.21) SEK |
Gross margin | 76 (72) % |
MAY 2024 – JANUARY 2025
Net sales | 10 796 (8 824) KSEK |
Operating result before depreciation (EBITDA) | -8 510 (-9 568) KSEK |
Net result | -12 280 (-14 826) KSEK |
Earnings per share | -0.34 (-0.58) SEK |
Gross margin | 71 (73) % |
IN SHORT
Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year.Gross margin continues to be strong, even slightly above planned levels (+4pp).Overall costs remain stable and as per plan; higher admin costs (capital raise connected) vs. lower R&D expenses.The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline & company potential.
CEO Commentary
Having recently taken on the role of acting CEO at PHI, my primary focus is execution—translating the Company’s potential into tangible results. We have a strong foundation built on deep technical expertise and a clear commitment to advancing regenerative medicine. Now, it’s time to maximize that potential.
Our path forward is clear: be the best at what we know best. This means focusing on cutting-edge imaging technology that empowers cell research and therapy, supported by a strong distributor network and strategic partnerships. Our recent financial performance demonstrates that we are moving in the right direction, with growing sales and a strong gross margin. However, we must accelerate further, ensuring our innovations reach the market at scale.
With a committed team, solid industry relationships, and a clear mission, we are ready to take PHI to the next level. The focus now is on execution and delivering on our promises—because the opportunity ahead is too great not to seize.
Ivan Jurkovic, CEO
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
För ytterligare information, vänligen kontakta:
Ivan Jurkovic
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
Ämnen i artikeln
Interim Report 3 2024/25
13 mars, 2025
Interim Report 3 2024/25
NOVEMBER 2024 – JANUARY 2025
Net sales | 6 481 (4 873) KSEK |
Operating result before depreciation (EBITDA) | -987 (-3 179) KSEK |
Net result | -2 681 (-5 152) KSEK |
Earnings per share | -0.08 (-0.21) SEK |
Gross margin | 76 (72) % |
MAY 2024 – JANUARY 2025
Net sales | 10 796 (8 824) KSEK |
Operating result before depreciation (EBITDA) | -8 510 (-9 568) KSEK |
Net result | -12 280 (-14 826) KSEK |
Earnings per share | -0.34 (-0.58) SEK |
Gross margin | 71 (73) % |
IN SHORT
Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year.Gross margin continues to be strong, even slightly above planned levels (+4pp).Overall costs remain stable and as per plan; higher admin costs (capital raise connected) vs. lower R&D expenses.The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline & company potential.
CEO Commentary
Having recently taken on the role of acting CEO at PHI, my primary focus is execution—translating the Company’s potential into tangible results. We have a strong foundation built on deep technical expertise and a clear commitment to advancing regenerative medicine. Now, it’s time to maximize that potential.
Our path forward is clear: be the best at what we know best. This means focusing on cutting-edge imaging technology that empowers cell research and therapy, supported by a strong distributor network and strategic partnerships. Our recent financial performance demonstrates that we are moving in the right direction, with growing sales and a strong gross margin. However, we must accelerate further, ensuring our innovations reach the market at scale.
With a committed team, solid industry relationships, and a clear mission, we are ready to take PHI to the next level. The focus now is on execution and delivering on our promises—because the opportunity ahead is too great not to seize.
Ivan Jurkovic, CEO
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
För ytterligare information, vänligen kontakta:
Ivan Jurkovic
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
Ämnen i artikeln
Din ekonomi
Analyser
Din ekonomi
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
